http://purl.org/np/RANucs0eEf... RANucs0eEf

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#type type

http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement Statement

Leoni Bücken

2021-06-14T06:56:34.513Z

http://purl.org/np/RANucs0eEf... RANucs0eEf

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/2000/01/rdf-schema#label label

for the management of schizophrenia trifluoperazine hydrochloride tablets usp are effective for the short term treatment of generalized non psychotic anxiety however trifluoperazine hydrochloride tablets are not the first drug to be used in therapy for most patients with non psychotic anxiety because certain risks associated with its use are not shared by common alternative treatments i e benzodiazepines when used in the treatment of non psychotic anxiety trifluoperazine hydrochloride tablets should not be administered at doses of more than 6 mg per day or for longer than 12 weeks because the use of trifluoperazine hydrochloride tablets at higher doses or for longer intervals may cause persistent tardive dyskinesia that may prove irreversible see warnings the effectiveness of trifluoperazine hydrochloride tablets as a treatment for non psychotic anxiety was established in a 4 week clinical multicenter study of outpatients with generalized anxiety disorder dsm iii this evidence does not predict that trifluoperazine hydrochloride tablets will be useful in patients with other non psychotic conditions in which anxiety or signs that mimic anxiety are found i e physical illness organic mental conditions agitated depression character pathologies etc trifluoperazine hydrochloride tablets have not been shown effective in the management of behavioral complications in patients with mental retardation

Leoni Bücken

2021-06-14T06:56:34.513Z

http://purl.org/np/RANucs0eEf... RANucs0eEf

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#object object

http://purl.obolibrary.org/obo/DOID_5419 DOID_5419

Leoni Bücken

2021-06-14T06:56:34.513Z

http://purl.org/np/RANucs0eEf... RANucs0eEf

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate predicate

https://w3id.org/biolink/vocab/treats treats

Leoni Bücken

2021-06-14T06:56:34.513Z

http://purl.org/np/RANucs0eEf... RANucs0eEf

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#subject subject

https://identifiers.org/drugbank:DB00831 drugbank:DB00831

Leoni Bücken

2021-06-14T06:56:34.513Z

http://purl.org/np/RANucs0eEf... RANucs0eEf

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/association_type association_type

https://w3id.org/biolink/vocab...OrPhenotypicFeatureAssociation ChemicalToDiseaseOrPhenotypicFeatureAssociation

Leoni Bücken

2021-06-14T06:56:34.513Z

http://purl.org/np/RANucs0eEf... RANucs0eEf

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/provided_by provided_by

https://w3id.org/um/NeuroDKG NeuroDKG

Leoni Bücken

2021-06-14T06:56:34.513Z

http://purl.org/np/RANucs0eEf... RANucs0eEf

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/relation relation

https://w3id.org/um/neurodkg/SymptomaticReliefIndication SymptomaticReliefIndication

Leoni Bücken

2021-06-14T06:56:34.513Z